PMID: 16443646

Van Goor F, Straley KS, Cao D, Gonzalez J, Hadida S, Hazlewood A, Joubran J, Knapp T, Makings LR, Miller M, Neuberger T, Olson E, Panchenko V, Rader J, Singh A, Stack JH, Tung R, Grootenhuis PD, Negulescu P
Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules.
Am J Physiol Lung Cell Mol Physiol. 2006 Jun;290(6):L1117-30. Epub 2006 Jan 27., [PubMed]
Sentences
No. Mutations Sentence Comment
87 ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 16443646:87:68
status: NEW
view ABCC7 p.Gly551Asp details
Fischer rat thyroid (FRT) epithelia expressing ⌬F508-CFTR or G551D-CFTR were grown on Costar Snapwell cell culture inserts for 4 days. Login to comment
263 ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 16443646:263:36
status: NEW
view ABCC7 p.Gly551Asp details
This includes the missense mutation G551D, which results in defective gating but does not impair trafficking to the apical membrane (9). Login to comment
264 ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 16443646:264:40
status: NEW
view ABCC7 p.Gly551Asp details
In FRT epithelial monolayers expressing G551D-CFTR, VRT-532 potentiated forskolin-stimulated Cl-secretion with an EC50 of 20 Ϯ 3 ␮M (n ϭ 3), which was about fivefold less potent than the EC50 observed for ⌬F508-CFTR in temperature-corrected FRT monolayers (EC50 ϭ 3.8 Ϯ 0.5 ␮M; n ϭ 46). Login to comment
358 ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 16443646:358:224
status: NEW
view ABCC7 p.Gly551Asp details
Although several potent CFTR potentiators have been reported in the literature, CFTR potentiator VRT-532 appears to be distinguished by its ability to potentiate the gating of several forms of CFTR, including ⌬F508-, G551D-, and wt-CFTR. Login to comment
359 ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 16443646:359:78
status: NEW
view ABCC7 p.Gly551Asp details
Like genistein (38), VRT-532 had an approximately fivefold lower affinity for G551D-CFTR than ⌬F508-CFTR. Login to comment
361 ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 16443646:361:0
status: NEW
view ABCC7 p.Gly551Asp details
ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 16443646:361:66
status: NEW
view ABCC7 p.Gly551Asp details
ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 16443646:361:116
status: NEW
view ABCC7 p.Gly551Asp details
G551D (ϳ70 nM and ϳ1,100 nM against ⌬F508- and G551D-CFTR, respectively) or are inactive against G551D-CFTR (benzothiophenes and sulfonamides) (38, 62). Login to comment
387 ABCC7 p.Arg117His
X
ABCC7 p.Arg117His 16443646:387:267
status: NEW
view ABCC7 p.Arg117His details
ABCC7 p.Ala455Glu
X
ABCC7 p.Ala455Glu 16443646:387:218
status: NEW
view ABCC7 p.Ala455Glu details
ABCC7 p.Arg334Trp
X
ABCC7 p.Arg334Trp 16443646:387:249
status: NEW
view ABCC7 p.Arg334Trp details
ABCC7 p.Arg347Pro
X
ABCC7 p.Arg347Pro 16443646:387:256
status: NEW
view ABCC7 p.Arg347Pro details
Genotype/phenotype correlations of Cl-channel function with disease severity show that mutations resulting in a only modest recovery toward wild-type levels (e.g., 5-30%) increase in CFTR expression or activity (e.g., A455E, 2,789 ϩ 5G3A, 5T, R334W, R347P, and R117H) and are typically associated with pancreatic sufficiency, a slower rate of pulmonary function decline, and a better severity index than that shown in patients with severe disease genotypes (5, 6, 10, 36, 49). Login to comment